These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 29025487

  • 1. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
    Zwerling A, Dowdy D, von Delft A, Taylor H, Merritt MW.
    Int J Tuberc Lung Dis; 2017 Nov 01; 21(11):69-74. PubMed ID: 29025487
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q, Ming WK, Yip WY, You JHS.
    Int J Infect Dis; 2019 Jan 08; 78():44-49. PubMed ID: 30342251
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ, Gibbert J, Wirth D, Diel R.
    Eur Respir J; 2015 Dec 08; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract] [Full Text] [Related]

  • 5. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 6. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 20; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 7. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE, Hill A.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1243-1252. PubMed ID: 28073970
    [Abstract] [Full Text] [Related]

  • 8. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 01; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 9. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Curr Opin Pulm Med; 2018 May 01; 24(3):244-252. PubMed ID: 29470252
    [Abstract] [Full Text] [Related]

  • 10. Bedaquiline and delamanid in tuberculosis.
    Esposito S, Bianchini S, Blasi F.
    Expert Opin Pharmacother; 2015 May 01; 16(15):2319-30. PubMed ID: 26293803
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May 01; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 12. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul 01; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.
    Emerg Infect Dis; 2017 Oct 01; 23(10):1718-21. PubMed ID: 28758888
    [Abstract] [Full Text] [Related]

  • 17. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Expert Opin Pharmacother; 2015 Oct 01; 16(18):2737-50. PubMed ID: 26478945
    [Abstract] [Full Text] [Related]

  • 18. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.
    Int J Tuberc Lung Dis; 2016 Feb 01; 20(2):177-86. PubMed ID: 26792469
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.